Elanco wins conditional nod for canine parvovirus therapy

• Elanco Animal Health (NYSE:ELAN) announced Tuesday that the U.S. Department of Agriculture (USDA) issued a conditional license for its canine parvovirus monoclonal antibody, the first of its kind therapy to treat one of the most contagious and deadly viral infections in dogs.
• Canine parvovirus is linked to a 91% mortality rate among dogs if not properly managed, and more than 330K canine parvovirus infections are reported annually in the U.S.
• Elanco’s (ELAN) single-dose intravenous antibody therapy is indicated for dogs aged eight weeks or older with canine parvovirus.
• “Elanco is proud to bring to market this first-in-class treatment that will help save puppies lives, while alleviating the emotional and financial burden of both pet owners and veterinary care teams,” Chief Executive Jeff Simmons remarked.
• The product shipments are expected to begin in the coming weeks, subject to state approvals.

More on ELAN

• Elanco Animal Health cat anemia drug wins FDA approval
• Elanco Animal Health: Reality Has Finally Caught Up